痴呆
神经认知
生物标志物
接收机工作特性
医学
神经心理学
疾病
内科学
过度诊断
神经心理评估
心理学
肿瘤科
认知
精神科
生物化学
化学
作者
Simona Aresta,Raffaello Nemni,Moreno Zanardo,G. Sirabian,Dario Capelli,Marco Alì,Paolo Vitali,Enrico Giuseppe Bertoldo,Valentina Fiolo,Lilla Bonanno,Giuseppa Maresca,Petronilla Battista,Francesco Sardanelli,Francesca B. Pizzini,Isabella Castiglioni,Christian Salvatore
标识
DOI:10.3389/fneur.2025.1568086
摘要
Introduction In 2024, 11 European scientific societies/organizations and one patient advocacy association have defined a patient-centered biomarker-based diagnostic workflow for memory clinics evaluating neurocognitive disorders. Methods We tested the performance of an artificial intelligence (AI) tool applied to neuropsychological and magnetic resonance imaging (MRI) assessment for staging and causal hypothesis, which are the two recommended workflow steps guiding the next one recommending optimal biomarkers to be used for a biological diagnosis of neurocognitive disorders, according to intersocietal recommendations. Moreover, we assessed the AI performance in predicting the progression to Alzheimer’s disease (AD)-dementia. Results For the three-class classification of staging (n patients = 426), the inter-rater AI-humans agreement was substantial for both healthy subjects/subjective cognitive impairment/worried-well vs. all the remaining groups (rest) (Cohen’s κ = 0.81) and mild cognitive impairment/mild dementia vs. rest κ = 0.70) classification, almost perfect for moderate/severe dementia vs. rest κ =0.90) classification. For the three-class classification of causal hypotheses ( n = 112), the AI performance vs. biomarker-based diagnosis was: positive predictive value 91% [95% CI: 84–96%]; negative predictive value 100%, and accuracy 91% [84–96%]. For the binary classification of progression or not progression to AD-dementia at 24-month, with clinical conversion as a reference standard ( n = 341), the AI performance was: sensitivity 89% [84–94%], specificity 82% [77–87%]; accuracy 85% [81–89%]; and area under the receiver operating characteristic curve 83% [79–87%]. Discussion The AI tool showed high agreement with human assessment for staging, high accuracy with biomarkers for causal hypotheses of neurocognitive disorders and predicted progression to AD at 24-month with 89% sensitivity and 82% specificity.
科研通智能强力驱动
Strongly Powered by AbleSci AI